For persistent depression, FDA approves a novel treatment based on ketamine

Tuesday, March 5, 2019 - 23:20 in Health & Medicine

The Food and Drug Administration approved a novel antidepressant — the first in decades to work in a completely new way in the brain — for people with depression that does not respond to other treatments. The drug, a nasal spray called esketamine, has been eagerly anticipated by psychiatrists and...

Read the whole article on LA Times - Science

More from LA Times - Science

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net